6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one

Modify Date: 2024-01-14 10:42:35

6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one structure	Common Name	6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one
	CAS Number	2095417-54-0	Molecular Weight	337.33
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₅H₁₉N₃O₆	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of 6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one

6-((2R,3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)-3-(2-oxopropyl)imidazo[1,2-c]pyrimidin-5(6H)-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].

Name	6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one

Description	6-((2R,3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)-3-(2-oxopropyl)imidazo[1,2-c]pyrimidin-5(6H)-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> Nucleoside Antimetabolite/Analog Research Areas >> Others
References	[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.

Molecular Formula	C₁₅H₁₉N₃O₆
Molecular Weight	337.33

6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one

Use of 6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-iMidazo[1,2-c]pyriMidin-5-one

Names

Biological Activity

Chemical & Physical Properties